Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients

[1]  Angela Mariotto,et al.  Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  B. Solomon,et al.  Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis , 2018, Annals of Surgical Oncology.

[3]  R. Jagsi,et al.  Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer , 2018, JAMA oncology.

[4]  K. Hunt,et al.  Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Kuerer,et al.  Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer , 2018, Cancer medicine.

[6]  H. Valdimarsdottir,et al.  Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients , 2018, Breast Cancer Research and Treatment.

[7]  C. Eng,et al.  Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients. , 2018, Journal of the American College of Surgeons.

[8]  Reshma Jagsi,et al.  Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Jemal,et al.  State Variation in the Receipt of a Contralateral Prophylactic Mastectomy Among Women Who Received a Diagnosis of Invasive Unilateral Early-Stage Breast Cancer in the United States, 2004-2012 , 2017, JAMA surgery.

[10]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[11]  A. Giuliano,et al.  Bilateral Mastectomy as Overtreatment for Breast Cancer in Women Age Forty Years and Younger with Unilateral Operable Invasive Breast Cancer , 2017, Annals of Surgical Oncology.

[12]  W. Barry,et al.  Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. , 2017, Annals of surgery.

[13]  K. Offit,et al.  Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer , 2017, Breast Cancer Research and Treatment.

[14]  R. Jagsi,et al.  Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer , 2016, JAMA surgery.

[15]  R. Tamimi,et al.  BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer. , 2016, JAMA oncology.

[16]  B. Jerome-D'Emilia,et al.  Why Women Are Choosing Bilateral Mastectomy. , 2015, Clinical journal of oncology nursing.

[17]  L. Esserman,et al.  Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer , 2015, Annals of Surgical Oncology.

[18]  H. Kuerer,et al.  Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative , 2015, Journal of Cancer.

[19]  K. Chung,et al.  Defining the Relationship between Patient Decisions to Undergo Breast Reconstruction and Contralateral Prophylactic Mastectomy , 2015, Plastic and reconstructive surgery.

[20]  A. Soran,et al.  Increasing trend of contralateral prophylactic mastectomy: what are the factors behind this phenomenon? , 2014, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[21]  J. Garber,et al.  Uptake of BRCA1/2 Genetic Testing in a Randomized Trial of Telephone Counseling , 2014, Genetics in Medicine.

[22]  C. Raker,et al.  Preoperative genetic testing affects surgical decision making in breast cancer patients. , 2014, Gynecologic oncology.

[23]  R. Tollenaar,et al.  Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis , 2014, International journal of cancer.

[24]  R. Jagsi,et al.  Social and Clinical Determinants of Contralateral Prophylactic Mastectomy. , 2014, JAMA surgery.

[25]  S. Mclaughlin,et al.  Impact of Breast Reconstruction on the Decision to Undergo Contralateral Prophylactic Mastectomy , 2014, Annals of Surgical Oncology.

[26]  W. Foulkes,et al.  Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis , 2014, BMJ : British Medical Journal.

[27]  I. Buchan,et al.  Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer , 2013, Breast Cancer Research and Treatment.

[28]  H. Valdimarsdottir,et al.  Intentions for bilateral mastectomy among newly diagnosed breast cancer patients , 2013, Journal of surgical oncology.

[29]  E. Levine,et al.  Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations. , 2011, American journal of surgery.

[30]  M. Morrow,et al.  Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[32]  H. Kuerer,et al.  Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy , 2010, Cancer Prevention Research.

[33]  U. Bick,et al.  Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Isaacs,et al.  Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors , 2006, Breast Cancer Research and Treatment.

[35]  C. Magnant,et al.  Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Susan L Neuhausen,et al.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Giovanni Parmigiani,et al.  BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[39]  D J Schaid,et al.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. , 1999, The New England journal of medicine.

[40]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  L. Derogatis,et al.  The Brief Symptom Inventory: an introductory report , 1983, Psychological Medicine.

[42]  M. Horowitz,et al.  Impact of Event Scale: A Measure of Subjective Stress , 1979, Psychosomatic medicine.

[43]  D. Penson,et al.  Nationwide trends in mastectomy for early-stage breast cancer. , 2015, JAMA surgery.